Abstract
Oral administration remains the most preferred route for the treatment of many diseases due to its convenience and adaptability. However, the presystemic metabolism may be an important barrier that prevents lipophilic drugs from achieving their pharmacological effects following oral delivery. Nano-based drug delivery system provides an effective strategy to reduce the presystemic metabolism and increase the systemic exposure of lipophilic drugs. In this review, we described the physiological factors affecting the presystemic metabolism of lipophilic drugs, intestinal transport of nanosystems, strategy of nanosystems to avoid the presystemic metabolism, and the current application of various oral nanosystems including lipid and polymeric nanocarriers. The nano-based drug delivery system has a lot of potential for reducing the presystemic metabolism and enhancing the bioavailability of orally administrated lipophilic drugs.
Keywords: Nanosystems, lipophilic drugs, presystemic metabolism, oral delivery, bioavailability, Nano-based Drug Delivery System, Oral Absorption, Lipophilic Drugs, Presystemic, Metabolism, anti-cancer drugs, inhibitors, ketoconazole, lumen.
Current Drug Metabolism
Title:Nano-based Drug Delivery System Enhances the Oral Absorption of Lipophilic Drugs with Extensive Presystemic Metabolism
Volume: 13 Issue: 8
Author(s): Zhiwen Zhang, Fang Gao, Shijun Jiang, Li Ma and Yaping Li
Affiliation:
Keywords: Nanosystems, lipophilic drugs, presystemic metabolism, oral delivery, bioavailability, Nano-based Drug Delivery System, Oral Absorption, Lipophilic Drugs, Presystemic, Metabolism, anti-cancer drugs, inhibitors, ketoconazole, lumen.
Abstract: Oral administration remains the most preferred route for the treatment of many diseases due to its convenience and adaptability. However, the presystemic metabolism may be an important barrier that prevents lipophilic drugs from achieving their pharmacological effects following oral delivery. Nano-based drug delivery system provides an effective strategy to reduce the presystemic metabolism and increase the systemic exposure of lipophilic drugs. In this review, we described the physiological factors affecting the presystemic metabolism of lipophilic drugs, intestinal transport of nanosystems, strategy of nanosystems to avoid the presystemic metabolism, and the current application of various oral nanosystems including lipid and polymeric nanocarriers. The nano-based drug delivery system has a lot of potential for reducing the presystemic metabolism and enhancing the bioavailability of orally administrated lipophilic drugs.
Export Options
About this article
Cite this article as:
Zhang Zhiwen, Gao Fang, Jiang Shijun, Ma Li and Li Yaping, Nano-based Drug Delivery System Enhances the Oral Absorption of Lipophilic Drugs with Extensive Presystemic Metabolism, Current Drug Metabolism 2012; 13 (8) . https://dx.doi.org/10.2174/138920012802850100
DOI https://dx.doi.org/10.2174/138920012802850100 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene Therapy for the Prevention of Ischemia / Reperfusion Injury in Organ Transplantation
Current Gene Therapy Protective Effects of Anesthetics on Vascular Function Related to K<sup>+</sup> Channels
Current Pharmaceutical Design LFA-1 as a Key Regulator of Immune Function: Approaches toward the Development of LFA-1-Based Therapeutics
Current Pharmaceutical Design Pharmacokinetics of Picroside I, II, III, IV in Rat Plasma by UPLCMS/ MS
Current Pharmaceutical Analysis Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design Galectin-1 is a Novel Factor that Regulates Myotube Growth in Regenerating Skeletal Muscles
Current Drug Targets Flavonols and Flavones – Protecting Against Myocardial Ischemia/ Reperfusion Injury by Targeting Protein Kinases
Current Medicinal Chemistry Therapeutic Benefit and Biological Importance of Ginkgetin in the Medicine: Medicinal Importance, Pharmacological Activities and Analytical Aspects
Current Bioactive Compounds Roles of TRPM7 in Renal Ischemia-Reperfusion Injury
Current Protein & Peptide Science Withdrawal Notice: Therapeutic Effect of Prdx1 on NAFLD Mice May be Related to the Activation of Nrf-2/HO-1 Pathway
Current Pharmaceutical Design Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Usefulness of Contrast-enhanced Ultrasound in the Evaluation of Chronic Kidney Disease
Current Medical Imaging Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Impact of Immunosuppressive Drugs on the Development of Cardiac Allograft Vasculopathy
Current Vascular Pharmacology Advances on Monosaccharides and Oligosaccharides: Structural Modifications and Bioactivities
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets ATP-Sensitive Potassium Channels
Current Pharmaceutical Design OPA1 in Cardiovascular Health and Disease
Current Drug Targets Cannabinoids and Myocardial Ischemia: Novel insights, Updated Mechanisms, and Implications for Myocardial Infarction
Current Medicinal Chemistry Autonomic Nervous System in Viral Myocarditis: Pathophysiology and Therapy
Current Pharmaceutical Design